natgillin/translations-raw huggingface dataset:
Pharmaceutical composition for use for altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein said pharmaceutical composition comprises nanoparticles or nanoparticles' aggregates and a pharmaceutically acceptable excipient, wherein each nanoparticle or nanoparticles' aggregate consists of a metal oxide selected from the group consisting of CeO2, Tm2O3, HfO2, WO3, and PdO, wherein the density of said nanoparticle or the density of said nanoparticles' aggregate is of at least 7,1 g/cm3 when the metal oxide is CeO2, of at least 8,3 g/cm3 when the metal oxide is Tm2O3, of at least 7,4 g/cm3 when the metal oxide is HfO2, of at least 7,2 g/cm3 when the metal oxide is WO3, and of at least 7,9 g/cm3 when the metal oxide is PdO, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Farmaceutski pripravak za uporabu u mijenjanju ili uništavanju ciljnih stanica u životinje kada se te stanice izlože ionizirajućim zračenjima, gdje taj farmaceutski pripravak sadrži nanočestice ili aggregate nanočestica i farmaceutski prikladnu pomoćnu tvar, pri čemu se svaka nanočestica ili agregat nanočestica sastoji od metalnog oksida odabranog iz skupine koju čine CeO2, Tm2O3, HfO2, WO3 i PdO, gdje je gustoća te nanočestice ili agregata nanočestica najmanje 7,1 g/cm3 ako je metalni oksid CeO2, najmanje 8,3 g/cm3 ako je metalni oksid Tm2O3, najmanje 7,4 g/cm3 ako je metalni oksid HfO2, najmanje 7,2 g/cm3 ako je metalni oksid WO3, i najmanje 7,9 g/cm3 ako je metalni oksid PdO, i gdje je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6.5 i 7.5 u fiziološkoj tekućini.
Pharmaceutical composition according to claim 19 or 20, wherein the metal oxide is HfO2 and the biocompatible coating is sodium trimetaphosphate (STMP) or sodium hexametaphosphate (HMP). 
Farmaceutski pripravak prema zahtjevu 19 ili 20, gdje je metalni oksid HfO2 i biorazgradiva ovojnica je natrijev trimetafosfat (STMP) ili natrijev heksametafosfat (HMP).
oxidation of the carbon-carbon double bond of ring D of 3-A-oxy-17-C-oxy-estra-1,3,5(10),15-tetraene VI to form protected estetrol VII, wherein A and C are protecting groups; and 
oksidacija dvostruke veze ugljik-ugljik prstena D 3-A-oksi-17-C-oksi-estra-1,3,5(10), 15-tetraena VI kako bi se dobio zaštitni estetrol VII, pri čemu su A i C zaštitne skupine; i
The process according to claim 1, wherein step (2) of the process is performed in the presence of a transition metal compound, and wherein the transition metal compound is a palladium compound. 
Postupak prema zahtjevu 1, u kome se korak (2) postupka provodi u prisutnosti spoja prijelaznog metala, i pri čemu je spoj prijelaznog metala paladijev spoj.
The process according to claim 7, wherein the palladium compound is a palladium(II) compound. 
Postupak prema zahtjevu 7, u kome je paladijev spoj, paladij (II) spoj.
The process according to claim 6 or claim 7, wherein the transition metal compound comprises palladium(II) acetate (Pd(OAc)2). 
Postupak prema zahtjevu 7 ili zahtjevu 8, u kome spoj prijelaznog metala sadrži paladij (II) acetat (Pd (OAc)2).
The process according to claim 10, wherein the oxidant is present in an amount of from 1 to 3 equivalents, relative to the amount of III. 
Postupak prema zahtjevu 10, u kome je oksidans prisutan u količini od 1 do 3 ekvivalenta, u odnosu na količinu III.
Process for the synthesis of 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one IV, wherein A is a protecting group, which comprises the steps of: 
Postupak sinteze 3-A-oksi-estra-1,3,5(10), 15-tetraen-17-on IV, pri čemu je A zaštitna skupina, koji obuhvaća sljedeće korake: [image]
B is -Si(R2)3, wherein R2 is independently selected from the group consisting of a C1 - C6 alkyl group and a C6 - C12 aryl group; wherein alkyl includes also cyclopropyl, cyclobutyl, cyclopentyl, methylcyclobutyl and cyclohexyl. 
B je -Si(R2)3, pri čemu je R2 neovisno odabran iz skupine koju čine C1 - C6 alkil skupina i C6 - C12 aril skupina; pri čemu alkil također uključuje i ciklopropil, ciklobutil, ciklopentil, metilciklobutil i cikloheksil.
A transdermal delivery device comprising: a polymer matrix layer comprising an opioid agonist with intermixed microspheres comprising an opioid antagonist, and wherein the microspheres are in a mean size of from 1 to 500 µm in diameter. 
Uređaj za transdermalno davanje koji sadrži: sloj polimerne matrice koji sadrži opioidni agonist s međusobno izmiješanim mikrosferama koje sadrže opioidni antagonist, te naznačen time da su mikrosfere u promjeru srednje veličine 1 do 500 µm.
The transdermal delivery device of claim 1, wherein the microspheres are in a mean size of from 125 to 200 µm, from 50 to 100 µm, from 1 to 200 µm, from 1 to 100 µm, or from 1 to 300 µm in diameter. 
Uređaj za transdermalno davanje prema zahtjevu 1, naznačen time da su mikrosfere u promjeru srednje veličine od 125 do 200 µm, od 50 do 100 µm, od 1 do 200 µm, od 1 do 100 µm, ili od 1 do 300 µm.
The transdermal delivery device of any one of claims 1 to 3, wherein the opioid antagonist becomes releasable if the transdermal delivery device is chewed, soaked, punctured, torn, or subjected to any other treatment which disrupts the integrity of the microspheres; and/or wherein the effect of the opioid agonist is at least partially blocked when the delivery device is chewed, crushed or dissolved in a solvent, or subject to any other treatment which disrupts the integrity of the microspheres, and administered orally, intranasally, parenterally or sublingually. 
Uređaj za transdermalno davanje prema bilo kojem od zahtjeva 1 do 3, naznačen time da se opioidni antagonist može osloboditi ako se uređaj za transdermalno davanje žvače, kvasi, buši, trga, ili podvrgava bilo kakvom drugom postupku koji narušava integritet mikrosfera; i/ili pri čemu se učinak opioidnog agonista barem djelomično blokira kada se uređaj za davanje žvače, gnječi ili rastapa u otapalu, ili podvrgava bilo kakvom drugom postupku koji narušava integritet mikrosfera, te se primjenjuje oralno, intranazalno, parenteralno ili sublingvalno.
The transdermal delivery device of any one of claims 1 to 4, wherein the polymer-matrix layer comprises a material selected from the group consisting of polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylenevinyl acetate copolymers, silicones, rubber, rubber-like synthetic homo-, co- or block polymers, polyacrylic esters and the copolymers thereof, polyurethanes, polyisobutylene, chlorinated polyethylene, polyvinylchloride, vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), ethylene-vinyl alcohol copolymer, ethylene-vinyloxyethanol copolymer, silicones (e.g., silicone copolymers such as polysiloxane-polymethacrylate copolymers), cellulose polymers (e.g., ethyl cellulose, and cellulose esters), polycarbonates, polytetrafluoroethylene and mixtures thereof. 
Uređaj za transdermalno davanje prema bilo kojem od zahtjeva 1 do 4, naznačen time da sloj polimerne matrice sadrži materijal odabran iz skupine koju čine polietilen, polipropilen, kopolimeri etilen/propilen, etilen/etilakrilat kopolimeri, kopolimeri etilenvinil acetat, silikoni, guma, gumasti sintetski homopolimeri, kopolimeri ili blok polimeri, poliakrilni esteri i njihovi kopolimeri, poliuretani, poliizobutilen, klorirani polietilen, polivinilklorid, vinil klorid-vinil acetat kopolimer, polimetakrilatni polimer (hidrogel), poliviniliden klorid, poli(etilen tereftalat), kopolimer etilen-vinil alkohol, kopolimer etilen-viniloksietanol, silikoni (npr., silikonski kopolimeri kao kopolimeri polisiloksan-polimetakrilat), celulozni polimeri (npr., etil celuloza, i celulozni esteri), polikarbonati, politetrafluoretilen i njihove smjese.
The transdermal delivery device of any one of claims 1 to 8, wherein the transdermal delivery device is a device selected from the group consisting of a transdermal patch, a transdermal plaster, a transdermal disc, and a iontophoretic transdermal device. 
Uređaj za transdermalno davanje prema bilo kojem od zahtjeva 1 do 8, naznačen time da uređaj za transdermalno davanje je uređaj odabran iz skupine koju čine transdermalni zavoj, transdermalni flaster, transdermalni disk, te iontoforetski transdermalni uređaj.
The immunogenic composition of claim 5 wherein said one or more S . pneumoniae proteins are selected from Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins, detoxified pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133. 
Imunogeni pripravak u skladu s patentnim zahtjevom 5, naznačen time što se navedeni jedan ili više proteina iz bakterije S. pneumoniae biraju između obitelji polihistidinske trijade (PhtX), obitelj kolinski vežućih proteina (CbpX), skraćenih CbpX, obitelji LytX, skraćenih LytX, kimernih proteina skraćenog CbpX-skraćenog LytX, detoksiciranog pneumolizina (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 i Sp133.
Pidotimod or a physiologically acceptable salt thereof for use according to claim 3, characterized in that it is administered by means of a semi-solid or liquid formulation. 
Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što se primjenjuje u obliku polučvrste ili tekuće formulacije.
The use according to claim 2, wherein said salt is crystalline. 
Spoj za uporabu prema zahtjevu 2, gdje je ta sol kristalična.
The use according to claim 3, wherein said salt is characterised by having major XRDP peaks at 6.89, 9.73, 13.78 and 14.62 (°2θ), all ± 0.1 (°2θ). 
Spoj za uporabu prema zahtjevu 3, gdje je ta sol, naznačena time što ima glavne pikove rendgenske difrakcije praška (XRDP) na 6.89, 9.73, 13.78 i 14.62 (°2θ), svi ± 0.1 (°2θ).
The method according to claim 4, wherein said salt is characterised by an XRDP as depicted in Figure 3. 
Spoj za uporabu prema zahtjevu 4, gdje je ta sol, naznačena XRDP-om kako je prikazan na Slici 3.
The use according to any of claims 1-7 provided compound I is not the free base of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in a non-crystalline form. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-7 uz uvjet da to nije slobodna baza 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina u ne-kristaličnom obliku.
Nutritional composition according to any one of the preceding claims wherein the lipid globules are at least partly coated on the surface with phospholipids, the amount of phospholipids present in the nutritional composition being from 0.5 to 20 wt.% phospholipids based on total lipid. 
Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva gdje su lipidne globule barem djelomično obložene fosfolipidima na površini, količina fosfolipida prisutnih u nutritivnom pripravku je od 0.5 do 20 tež.% fosfolipida u odnosu na ukupne lipide.
A pharmaceutically acceptable salt of the compound: wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide and phosphate salt. 
Farmaceutski prihvatljiva sol spoja: [image] pri čemu je farmaceutski prihvatljiva sol izabrana iz grupe koja se sastoji od hidrokloridne, hidrobromidne, hidrojodidne i fosfatne soli.
A pharmaceutical composition comprising a pharmaceutically acceptable salt of claim 1 and at least one pharmaceutically acceptable excipient. 
Farmaceutski sastav koji sadrži farmaceutski prihvatljivu sol iz patentnog zahtjeva 1 i najmanje jedan farmaceutski prihvatljiv ekscipijens.
The pharmaceutical composition according to claim 7, wherein the pharmaceutically acceptable salt is the hydrochloride salt. 
Farmaceutski sastav prema patentnom zahtjevu 7, pri čemu je farmaceutski prihvatljiva sol, hidrokloridna sol.
The pharmaceutical composition of claim 5, wherein the compound is the S-enantiomer. 
Farmaceutski sastav iz patentnog zahtjeva 5, pri čemu je spoj S-enantiomer.
The kit according to claim 9 wherein the compound is the S-enantiomer. 
Komplet prema patentnom zahtjevu 9 pri čemu je spoj S-enantiomer.
A method for producing a sweet juice composition, comprising: 
Postupak proizvodne sastava slatkog soka, obuhvaća:
providing a cation exchange resin and an anion exchange resin, wherein the cation exchange resin is regenerated in acid form, and wherein the anion exchange resin is regenerated in alkali form; 
pružanje smole za izmjenu kationa i smole za izmjenu aniona, pri čemu je smola za izmjenu kationa regenerirana u obliku kiseline, i pri čemu je smola za izmjenu aniona regenerirana u alkalnom obliku;
contacting the partially processed juice with the anion exchange resin to produce a sweet juice composition, wherein the sweet juice composition retains at least 60% of the mogroside V from the juice as determined by high-pressure liquid chromatography (HPLC). 
spajanje djelomično prerađenog soka sa smolom za izmjenu aniona kako bi se proizvelo sastav slatkog soka, pri čemu sastav slatkog soka zadržava barem 60% mogrosida V iz soka kako je utvrđeno tekućinskom kromatografijom visokog tlaka (HPLC).
The method of claim 1, wherein the sweet juice composition retains at least 60% of the terpene glycosides from the juice as determined by HPLC. 
Postupak sukladno zahtjevu 1, pri čemu sastav slatkog soka zadržava barem 60% terpenskog glikozida iz soka kako je određeno pomoću HPLC.
The method of claim 4, further comprising clarifying the juice before contact with the cation exchange resin. 
Postupak sukladno zahtjevu 4, nadalje obuhavaća pročišćavanje soka prije dodira sa smolama za izmjenu kationa.
The method of any one of claims 1 to 7, wherein the acid form is selected from the group consisting of hydrogen form, ammonium form, and a combination thereof, and/or wherein the alkali form is selected from the group consisting of hydroxyl form, carbonate form, and a combination thereof. 
Postupak sukladno bilo kojem od zahtjeva 1 do 7, pri čemu je kiseli oblik odabran iz skupine koja se sastoji od vodika, amonijaka, i njihovih kombinacija, i/ili pri čemu je alkalni oblik odabran iz skupine koja obuhvaća hidroksilni oblik, karbonatni oblik, i njihove kombinacije.
The method of any one of claims 1 to 9, wherein the cation exchange resin is regenerated in hydrogen form, and the anion exchange resin is regenerated in hydroxyl form. 
Postupak sukladno bilo kojem od zahtjeva 1 do 9, pri čemu je smola za izmjenu kationa regenerirana u obliku vodika, a smola za izmjenu aniona je regenerirana u obliku hidroksila.
A method for producing a sweet juice composition, comprising: 
Postupak proizvodnje sastava slatkog soka, obuhvaća:
providing a cation exchange resin and an anion exchange resin, wherein the cation exchange resin is regenerated in acid form, and wherein the anion exchange resin is regenerated in alkali form; and 
pružanje smole za izmjenu kationa i smole za izmjenu aniona, pri čemu je smola za izmjenu kationa regenerirana u obliku kiseline, i pri čemu je smola za izmjenu aniona regenerirana u alkalnom obliku; i
contacting the partially processed juice with the anion exchange resin to produce a sweet juice composition, wherein the sweet juice composition retains at least 60% of the mogroside V from the juice as determined by high-pressure liquid chromatography (HPLC), 
spajanje djelomično prerađenog soka sa smolom za izmjenu aniona kako bi se proizvelo sastav slatkog soka,npri čemu sastav slatkog soka zadržava barem 60% mogrosida V iz soka kako je utvrđeno tekućinskom kromatografijom visokog tlaka (HPLC), pri čemu je opcionalno sok pružen u koraku (a):
a fresh juice, and wherein the ratio of cation exchange resin to anion exchange resin is about 1 to 1; or a diluted juice, and wherein the ratio of cation exchange resin to anion exchange resin is about 1.4-2 to 1. 
svježi sok, i pri čemu je omjer smole za kationsku izmjenu i smole za anionsku izmjenu otprilike 1 prema 1; ili razrijeđeni sok, i pri čemu je omjer smole za kationsku izmjenu i smole za anionsku izmjenu oko 1.4-2 prema 1.
A compound of formula (I) or a salt thereof according to claim 1, selected from the list consisting of: 
Spoj sa formulom (I) ili njegova sol prema patentnom zahtjevu 1, odabrano sa liste koji se sastoji od:
A compound of formula (I) as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, or psoriasis. 
Spoj sa formulom (I) kao što je definirano prema bilo kojem od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, za primjenu u liječenju reumatoidnog artritisa, vaskulitisa, eritemskog sistemskog lupusa, ulcerativnog kolitisa, raka, cistične fibroze, astme, kutanog eritemskog lupusa, ili psorijaze.
• the buprenorphine is present as the free base (unprotonated) form; 
• buprenorfin je prisutan u obliku slobodne baze (neprotoniran);
The composition for the use according to any preceding claim which provides treatment for opioid dependence over a period of no more than 30 days. 
Supstanca za upotrebu prema patentnom zahtjevu 6 pri čemu ova supstanca osigurava terapiju kod ovisnosti o opijatima ili ublažavanje bolova tokom perioda koji nije duži od 30 dana.
The composition for the use according to any of claims 8 to 13, wherein the dosage achieves a therapeutically effective level of the buprenorphine, metabolite, or prodrug thereof within about one day after administration of the composition; and wherein the therapeutically effective dosage of the buprenorphine, metabolite, or prodrug thereof is delivered for at least about 7 days after administration of the composition, or for at least about 30 days after administration of the composition. 
Supstanca za upotrebu prema bilo kom od patentnih zahtjeva 6 do 11, pri čemu ova doza dostiže terapijski djelotvoran nivo buprenorfina ili njegovog metabolita u roku od jedan dan posle primjene ove supstance; i pri čemu se terapijski djelotvorna doza buprenorfina, ili njegovog metabolita isporučuje tokom najmanje 7 dana poslije primjene ove supstance, ili tokom najmanje oko 30 dana poslije primjene ove supstance.
The modular antibody according to claim 12, wherein the protein fused to the modular antibody is selected from the group consisting of other modular antibodies, immunoglobulins, ligands, scaffold proteins, enzymes, and toxins. 
Modularno antitijelo prema patentnom zahtjevu 8, gdje je protein fuzioniran za modularno antitijelo odabran iz grupe koja se sastoji od drugih modularnih antitijela, imunoglobulina, laganada, proteina skele (“scaffold”), enzima, i toksina.
Solid composition for oral administration containing at least one dye in association with at least one physiologically acceptable excipient, characterised in that it comprises: 
Čvrsti pripravak za oralnu primjenu koji sadrži barem jednu boju zajedno s barem jednom fiziološki prikladnom pomoćnom tvari, naznačen time što sadrži:
a matrix which consists of lipophilic compounds with melting point below 90°C, and optionally amphiphilic compounds, in which said at least one dye is at least partly incorporated; 
matriks koji se sastoji od lipofilnih spojeva s talištem nižim od 90°C, i amfifilnih spojeva, gdje je barem jedna boja barem djelomično inkorporirana;
A composition of 4 peptides from a mammalian telomerase, comprising: 
Sastav od 4 peptida iz telomeraze sisavca, sadrži:
three HLA class II restricted peptides in combination with an adjuvant, wherein: 
tri ograničena peptida HLA razreda II u kombinaciji s adjuvansom, gdje:
The composition of claim 1 wherein said telomerase is human. 
Sastav iz patentnog zahtjeva 1 gdje je navedena telomeraza ljudska.
The composition according to any one of claims 1 and 2 for use in medicine. 
Sastav u skladu s bilo kojim od patentnih zahtjeva 1 i 2 za uporabu u medicini.
The composition according to any one of claims 1 and 2 for use in human medicine. 
Sastav u skladu s bilo kojim od patentnih zahtjeva 1 i 2 za uporabu u ljudskoj medicini.
The composition for the use according to anyone of claims 3 and 4 as a vaccine for renal or prostate cancer. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 3 i 4 kao cjepivo za rak bubrega i prostate.
The composition for the use according to claim 5 wherein said renal or prostate cancer is advanced. 
Sastav za uporabu u skladu s patentnim zahtjevom 5 pri čemu je navedeni rak bubrega ili prostate uznapredovao.
The composition according to any one of claims 1 and 2, suitable for administration by intradermal injection. 
Sastav u skladu s bilo kojim od patentnih zahtjeva 1 i 2, pogodan za davanje intradermalnom injekcijom.
A thermoplastic polymer formulation containing polyamides (PA) and/or EVOH and polyolefins, characterized in that it also comprises a polypropylene homopolymer with MFI in the range of 15 to 50, preferably 20 to 50, (g/10min, ASTM 1238L), as a compatibilizer between said PA and/or EVOH and polyolefin polymers; wherein the quantity of said PP homopolymer is in the range of 15% to 50% by weight and the formulation further comprises a PP (co)polymer different from the above mentioned PP homopolymer. 
Termoplastična polimerna formulacija koja sadrži poliamide (PA) i/ili EVOH i poliolefine, naznačena time, da ona također sadrži polipropilen homopolimer s MFI (indeks tečenja taline) u području od 15 do 50, prvenstveno 20 do 50 (g/10min, ASTM 1238L), kao kompatibilizator između navedenih PA i/ili EVOH i poliolefinskih polimera, u čemu je količina navedenog PP homopolimera u području od 15 do 50 tež.%, a formulacija nadalje sadrži PP (ko)polimer koji je različit od gore navedenog PP homopolimera.
A formulation according to claim 1 or 2, wherein said PA and/or EVOH and polyolefins (PE, PP) derive at least in part from waste materials from the production of multilayer films containing two or more of PE, PA, PP, EVOH, and wherein these materials are present in an amount in the range of 10% to 70%, preferably 25% to 35% by weight of the final formulation weight. 
Formulacija prema patentnom zahtjevu 1 ili 2, naznačena time, da navedeni PA i/ili EVOH i poliolefini (PE, PP) proizlaze barem djelomično iz otpadnih materijala od proizvodnje višeslojnih folija koje sadrže dva ili više PE, PA, PP, EVOH, i gdje su ti materijali prisutni u količini u području od 10 do 70%, prvenstveno 25 do 35 tež.% u odnosu na konačnu težinu formulacije.
A formulation according to any of claim 1 to 3, further comprising a PP filled with inorganic and/or organic fillers, said filled PP being present in a quantity between 15% to 40%, preferably 25% and 35% by weight of the final formulation weight. 
Formulacija prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time, da nadalje sadrži PP punjen anorganskim i/ili organskim punilima, a navedeni PP s punilom je prisutan u količini od 15 do 40, prvenstveno 25 i 35 tež.% u odnosu na konačnu težinu formulacije.
A formulation according to claim 4, wherein said mineral filler is CaCO3 and said organic filler is wood. 
Formulacija prema patentnom zahtjevu 4, naznačena time, da navedeno mineralno punilo jest CaCO3, a navedeno organsko punilo jest drvo.
A formulation according to claim 8, wherein the materials a) - d) derive from production waste of multilayer films. 
Formulacija prema patentnom zahtjevu 8, naznačena time, da materijali a) do d) proizlaze iz otpada od proizvodnje višeslojne folije.
A process according to claim 16, comprising a step of drying and/or dehumidifying said waste materials. 
Postupak prema patentnon zahtjevu 16, naznačen time, da sadrži stupanj sušenja i/ili odvlaživanja navedenih otpadnih materijala.
providing an immunoglobulin solution with a concentration of at least 100 g/l, 
pripremanje otopine imunoglobulina s koncentracijom od najmanje 100 g/l;
optionally adding a sugar, an amino acid and/or a detergent to the solution, 
prema potrebi dodavanje šećera, aminokiseline i/ili deterdženta u otopinu;